ProShares Ultra Nasdaq Biotechnology (NASDAQ:BIB - Get Free Report) was the recipient of a large increase in short interest during the month of January. As of January 15th, there was short interest totalling 5,200 shares, an increase of 136.4% from the December 31st total of 2,200 shares. Based on an average trading volume of 10,900 shares, the days-to-cover ratio is currently 0.5 days.
Hedge Funds Weigh In On ProShares Ultra Nasdaq Biotechnology
A hedge fund recently raised its stake in ProShares Ultra Nasdaq Biotechnology stock. Jane Street Group LLC boosted its position in ProShares Ultra Nasdaq Biotechnology (NASDAQ:BIB - Free Report) by 8.4% during the 3rd quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The firm owned 4,803 shares of the exchange traded fund's stock after buying an additional 374 shares during the period. Jane Street Group LLC owned approximately 0.35% of ProShares Ultra Nasdaq Biotechnology worth $306,000 at the end of the most recent quarter.
ProShares Ultra Nasdaq Biotechnology Price Performance
Shares of BIB traded down $0.52 on Monday, hitting $55.11. The company's stock had a trading volume of 25,776 shares, compared to its average volume of 9,188. ProShares Ultra Nasdaq Biotechnology has a fifty-two week low of $47.19 and a fifty-two week high of $69.56. The firm's fifty day moving average price is $54.17 and its 200-day moving average price is $60.31.
ProShares Ultra Nasdaq Biotechnology Increases Dividend
The business also recently disclosed a dividend, which was paid on Tuesday, December 31st. Shareholders of record on Monday, December 23rd were issued a $0.3964 dividend. This is an increase from ProShares Ultra Nasdaq Biotechnology's previous dividend of $0.15. The ex-dividend date of this dividend was Monday, December 23rd.
ProShares Ultra Nasdaq Biotechnology Company Profile
(
Get Free Report)
ProShares Ultra Nasdaq Biotechnology (the Fund) seeks daily investment results, before fees and expenses, that correspond to twice (200%) the daily performance of the Index. The return of the Fund for a period longer than a single trading day will be the result of each day's returns compounded over the period, which will very likely differ from the inverse of the return of the Dow Jones United States Basic Materials Index (the Index) for that period.
Further Reading
Before you consider ProShares Ultra Nasdaq Biotechnology, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and ProShares Ultra Nasdaq Biotechnology wasn't on the list.
While ProShares Ultra Nasdaq Biotechnology currently has a "Hold" rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Enter your email address and we'll send you MarketBeat's list of the 10 best stocks to own in 2025 and why they should be in your portfolio.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.